The shares of Danish vaccine company Bavarian Nordic (BAVA.DK) are gaining nearly 7% today after reporting preliminary results for 2022. Despite an increase in research spending, the company raised its forecasts, and results far exceeded analysts' expectations:
- Revenues for the full year 2022 amounted to DKK 3.15 billion, compared to DKK 2,800 to 3,000 billion forecast by the market. They were primarily made up of revenues from smallpox vaccine, JYNNEOS, IMVANEX and IMVAMUNE, which accounted for more than half of revenues, DKK 1.73 billion. This was followed by valor supported by DKK 879 million in revenue from Rabipur and RabAvert vaccines, DKK 299 million from Encepur vaccine sales, DKK 79 million in profit from trading other companies' products, and DKK 164 million in revenue from other medical activities.
- EBITDA was more or less DKK 329 million, compared to a projected loss in the range of DKK - 200 to 0 million. Cash and cash equivalents at year-end amounted to DKK 1.74 billion, compared to forecasts of well below DKK 1.7 billion. The forecast also assumed a high level of bank debt at the end of 2022 of DKK 600 million, but the bank debt was repaid in the fourth quarter of the year. The improvement in revenues was largely due to high demand for smallpox vaccines. The continued strong performance of the rabies vaccine business also contributed to the improvement.
Paul Chaplin, the company's president and CEO, commented on the results: "Compared to our original forecast for 2022, we nearly tripled our revenue and turned into a profitable business (...) We were expected to burn our cash as we launched two large Phase 3 trials that were driving significant R&D costs. It was a remarkable year and we are very pleased to announce these results, which were made possible primarily by the significant influx of orders for our smallpox vaccine during the year. It is very encouraging that we were able to advance our promising late-stage product line and still achieve such good financial results for the year."
Bavarian Nordic (BAVA.DK) shares, W1 interval. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
